Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway

BACKGROUND: Fatty acid synthase (FASN) is overexpressed in most human carcinomas, including non-small cell lung cancer (NSCLC), and contributes to poor prognosis. An increasing number of studies have highlighted the potential function of FASN as both a biomarker and therapeutic target for cancers. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ligong, Fang, Surong, Chen, Yubao, Yang, Zhenhua, Yuan, Yuan, Zhang, Jing, Ye, Liang, Gu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533754/
https://www.ncbi.nlm.nih.gov/pubmed/31122252
http://dx.doi.org/10.1186/s12944-019-1058-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533754/
https://www.ncbi.nlm.nih.gov/pubmed/31122252
http://dx.doi.org/10.1186/s12944-019-1058-8

Ejemplares similares